Growing Application of Pharmacoeconomics and Outcomes Research in Health-Care Decision-Making in the Asia-Pacific Region  by Yang, Bong-min & Lee, Kenneth
Growing Application of Pharmacoeconomics and
Outcomes Research in Health-Care Decision-Making
in the Asia-Paciﬁc Regionvhe_618 1..2
Bong-min Yang, PhD,1 Kenneth Lee, PhD2
1Seoul National University, Seoul, Korea; 2Chinese University of Hong Kong, Hong Kong, China
Resource scarcity in health-care delivery, as in other sectors of the
economy, is a globally common phenomenon. Among the con-
tributing factors to resource scarcity in health care, prime factors
are the introduction of new health technologies (NHT), an indi-
vidual’s growing awareness of better health status, and popula-
tion aging. Resulting issues from resource scarcity raise deep
concerns for Asian policymakers and stakeholders in health care.
With the recognition that market imperfection prevails with
the use of NHT, a regulatory body may well intervene in the
market of NHTs with the objective of establishing a standard for
NHT adoption and the curtailing of nonrational use of NHTs.
Based on the experiences of several Western economies, Asian
communities have found much promise in the use of health
technology assessment (HTA) as a policy tool for NHT manage-
ment. Interest in HTA is signiﬁcant in Asia, as was evidenced in
the ISPOR 3rd Asia-Paciﬁc Conference held in Seoul, Korea, in
September 2008. With “Evidence-Based Health-Care Decision-
Making in Asia-Paciﬁc: The Application of Pharmacoeconomics
and Outcomes Research” as the theme, the Conference was
well-received by active participants from mostly Asian countries.
By and large, the attendees in HTA meetings can be grouped
into two parties, one representing technology developers and the
other representing those in research and policy. Interestingly, the
two groups are coming to the meetings for the same reason—that
HTA policy may well be adopted at their local settings sooner or
later. Considering local resource constraints in health-care deliv-
ery in most countries, whether developed or developing, NHT
can quickly be pinpointed as a promising area for resource man-
agement because unlike new technologies in other sectors, NHT
are mostly cost-increasing rather than cost-saving. The majority
in the ﬁeld therefore believes that a type of rationing scheme with
NHT is inevitable and should be implemented sooner than later.
Resource constraint in health care is becoming even more
prominent an issue in Asia than in other regions. NHT develop-
ers view Asia as very attractive for two reasons: ﬁrst, it is already
a big market with a large population size, and second, it is a
growing market with relatively higher economic growth rates
and comparatively greater speed of population aging. As HTA
policy has been formulated in parts of the region in recent years,
NHT developers have become keenly interested in their policy
contents and their impact on business. By attending HTA meet-
ings and exchanging dialogue, NHT developers hope to learn
how to cope with the changes brought on by HTA adoption.
Researchers and policymakers attend meetings to see what can be
done in the context of their own country and how to improve
ongoing policy situations. The understanding they commonly
share as they attend HTA meetings is that rationing is inevitable,
and that HTA could be an option now or some time in the future
[1].
The implementation of HTA guidelines in a few Asian coun-
tries including South Korea, Taiwan, and Thailand in the last few
years marks the catching up of Asia with the Western counter-
parts at a remarkable speed in the generation and utilization of
health economic data. With the world’s attention becoming more
and more focused in Asia, a phenomenon which is likely to
continue for decades to come, it is only natural and legitimate
that an evidence-based approach should be adopted in deciding
health-care resource utilization. This is of utmost importance in
providing a favorable environment for both the adoption of new
HTAs as well as improving the standard of health care across
Asia.
The ISPOR Asia Consortium was established in 2004 and is
now in its sixth year of operation. Under the unfailing support of
the mother society, a number of major achievements have been
made possible in a period of merely 6 years and it is now the
largest regional chapter under the auspices of ISPOR. It began
with a membership of around 10 and now over 70 individuals
from research institutes; academia, consulting, and industry are
listed either as executive or advisory board members. With the
increased experience of the members concerned, the biennial
ISPOR Asia-Paciﬁc meeting has been increasingly well-attended
and highly commended. For example, at the 3rd ISPOR Asia-
Paciﬁc Conference in Seoul, South Korea, more than 850 people
from government, academics, research institutions, and private
companies registered and exchanged research ﬁndings, ideas,
opinions, and policy experiences during the 3-day event. Attend-
ees came from 38 countries or areas, mostly from the Asian
region. The number of attendees and participating countries have
been signiﬁcantly increasing with each Conference. Such growth
would not have been possible without the vision of the founders
and the enthusiasm and dedication of the members.
Yet behind the scene, it is not without worries. Although it is
very encouraging to see an obvious trend of an increased use of
HTA in decision-making, we should also admit that we are still
falling behind in terms of skills level, appropriate data base,
methodology, and manpower. In many occasions in Asia, for
example, effectiveness and efﬁcacy data from one’s own popula-
tion setting are not available. It is also difﬁcult for a party to
carry out separate clinical experimentation to get such data from
its own people. Under these circumstances, the responsible party
(government, research institute, or pharmaceutical company)
often relies upon foreign outcome data for domestic economic
evaluation data construction. Nevertheless, it would not be safe
to use foreign outcome-related clinical data without modiﬁca-
tions, considering possible variations stemming from genetic dif-
ferences. Differences in medical practice patterns among
countries would also result in a different scale of effectiveness.
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Another aspect of challenge is with the measurement of utili-
ties of the Asians. For technical assistance in measuring utility,
tools such as EuroQoL and Health Utility Index are often used.
Nevertheless, as these tools have mostly been developed in
Europe and North America, they may fail to reﬂect Asian cul-
tural preferences, even after the reliability and validity of the
questionnaires for certain Asian populations have been tested.
Currently, economic evaluation studies in most Asian countries
use the Western tools with no changes in preference measure. The
corresponding utility estimates could therefore be a less accurate
representation of Asian preference values.
Resources availability and support from individual local gov-
ernments are still lacking. Doubt and hesitation in using health
economic data are still common among government ofﬁcials and
major decision-makers. All these can be signiﬁcant obstructions
in leading our way forward. In short, we are only approaching
the end of the beginning, lots and lots remain to be attended to.
Since ISPOR launched the 1st Asia-Paciﬁc Conference, Kobe,
Japan in 2003, we have witnessed enormous growth of health
economics and outcomes research in Asia. For the journal of
Value in Health, it was prominent progress to have the 1st Asia
Special Issue published after the 2nd Asia-Paciﬁc Conference,
Shanghai, China 2006. Today, we celebrate another such event as
some of the key deliberations of the 3rd Asia-Paciﬁc Conference,
Seoul, Korea 2008 are being published in the 2nd Asia Special
Issue.
There are 24 articles in this special supplement. Articles were
selected mostly from the ISPOR 3rd Asia-Paciﬁc Conference held
in Seoul. After going through the usual anonymous process
of peer review, selected articles were grouped into two
categories—“full” and “condensed” articles. Among the 10 full
articles are three multi-country articles, covering HTA policies in
a total of 10 Asian health-care systems (China, India, Japan,
Malaysia, Pakistan, Philippines, Singapore, South Korea,
Taiwan, and Thailand). The rest are articles developed from
either plenary talks or parallel/poster presentations. The articles
cover a wide range of HTA-related scientiﬁc issues such as soci-
etal burden of disease, cost effectiveness of various interventions,
policy development, incremental cost-effectiveness ratio thresh-
old, utility measurement tool, HTA attitudes among decision-
makers and researchers, pharmacoeconomic submission
guideline, and outcomes measurement. Published articles in the
Asia Special Issue vividly show how actively and seriously the
issues of HTA are being contemplated and pursued by stakehold-
ers in the region. They showcase a wide range of application of
economic evaluation and outcomes research and its territorial
expansion in the region.
In the process of editorial efforts, we recognized some articles
attained high standards of research, while others were question-
able in terms of scientiﬁc soundness. As the multi-disciplinary
sciences in health care are still developing in Asia, scientiﬁc
research methods with high integrity must be adopted and
enforced.
The use of HTA in health-care delivery is the track that every
country in Asia is interested in and is contemplating following in
the future. The adoption of HTA will likely occur on various
timelines for the different countries in the region. The contents of
policy actions could also be varied among countries, depending
on the policy culture, the current health-care system, and public
trust in government bureaucracy. In moving toward the direction
of HTA adoption in Asia, we hope this special issue of Value in
Health will provide researchers and policymakers in Asia with a
higher level of motivation to engage in science-based research
and evidence-based policymaking. We believe it will contribute to
the mission toward a better future in Asia.
The 4th ISPOR Asia-Paciﬁc Conference will be held in
Phuket, Thailand, in September 2010. Planning and preparation
for the Conference is already underway. It is, however, the
support and participation of the members that is of core impor-
tance in guaranteeing another round of success. In a few years,
we will be celebrating our 10-year anniversary and we hope that
everyone’s efforts and dedication will allow us to look back
together with great pride and sense of service.
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